M₁ muscarinic agonist treatment reverses cognitive and cholinergic impairments of apolipoprotein E-deficient mice

Medicine & Life Sciences

• Muscarinic Agonists 68%
• Apolipoproteins E 54%
• Cholinergic Agents 48%
• Cognitive Dysfunction 42%
• 1-methylpiperidine-4-spiro-(2'-methylthiazoline) 15%
• Alzheimer Disease 15%
• Short-Term Memory 12%
• Brain 9%
• Apolipoprotein E4 8%
• Therapeutics 8%
• Basal Forebrain 8%
• Choline O-Acetyltransferase 7%
• Cholinergic Neurons 7%
• Acetylcholinesterase 7%
• Memory Disorders 6%
• Knockout Mice 5%

Chemistry

• Muscarinic M1 Receptor Agonist 100%
• Cholinergic 65%
• Apolipoprotein 63%
• Muscarinic Agonist 9%
• Parasympathomimetic Agent 8%
• Choline 6%
• Agonist 6%
• Marker 5%